Systemic Sclerosis Protocol: Comprehensive Evaluation

Forty-three SSc patients followed at Siena University Hospital were consecutively enrolled from September 2020 to June 2021. Patients fulfilling 2013 ACR/EULAR SSc classification criteria were enrolled [5 (link)]. The following data were collected for each patient: age, sex, body mass index (BMI), smoking history, hypertension, disease duration, DU (active DU or previous healed DU), modified Rodnan skin score (mRSS), type of cutaneous involvement (limited/diffuse), serum anticentromere antibodies (ACA), anti PM/Scl antibodies, anti-topoisomerase I antibodies (Scl-70), pulmonary artery pressure (PAPs) expressed in mmHg and left ventricular ejection fraction (FE%) evaluated at echocardiography, diffusion capacity for carbon monoxide (DLCO), nailfold-video-capillaroscopy (NVC) pattern (early, active and late) and macrovascular CDUS parameters (RI and PV). Treatment at the time of the evaluation was reported: antiplatelet therapy, calcium channel blockers, iloprost, endothelin receptor antagonists (ERA), phosphodiesterase inhibitors, immunosuppressive treatment (mycophenolate mofetil, methotrexate, azathioprine, rituximab), nintedanib and steroids. The results from the SSc group were compared to those of a group of patients affected by primary RP (n = 23) and to HCs (n = 22). Data regarding RP and DU severity and diagnosis of pulmonary hypertension made by right heart catheterization were not evaluated. All patients were evaluated under vasodilator treatment except for those receiving iloprost, who were evaluated on a different day with respect to the treatment. All patients gave their own written informed consent. This study was specially approved by the ethical committee of “Azienda Ospedaliero Universitaria Senese” (protocol number: RHELABUS 22271).

Free full text: Click here

D’Alessandro R., Garcia Gonzalez E., Falsetti P., Conticini E., d’Alessandro M., Selvi E., Bellisai F., Berlengiero V., Vallifuoco G., Pata A.P., Bardelli M., Baldi C., Cantarini L., Bargagli E, & Frediani B. (2023). Peripheral Macrovascular Involvement in Systemic Sclerosis: A Cohort Study by Color and Spectral Doppler Ultrasonography. Life, 13(2), 487.

Publication 2023

Anti antibodies Anti topoisomerase i antibodies Anticentromere antibodies Azathioprine Body mass index Calcium channel blockers Carbon monoxide Diagnosis Diffusion Echocardiography Endothelin receptor antagonists Heart catheterization Hypertension Iloprost Immunosuppressive Methotrexate Mycophenolate mofetil Nailfold capillaroscopy Nintedanib Paps Patients Phosphodiesterase inhibitors Pressure Pulmonary artery Pulmonary hypertension Rituximab Serum Steroids Type Vasodilator Ventricular ejection fraction

Corresponding Organization : University of Siena

Top 5 similar protocols

Variable analysis

independent variables

Body mass index (BMI)
Smoking history
Hypertension
Disease duration
DU (active DU or previous healed DU)
Type of cutaneous involvement (limited/diffuse)
Serum anticentromere antibodies (ACA)
Anti PM/Scl antibodies
Anti-topoisomerase I antibodies (Scl-70)
Treatment at the time of the evaluation (antiplatelet therapy, calcium channel blockers, iloprost, endothelin receptor antagonists, phosphodiesterase inhibitors, immunosuppressive treatment, nintedanib, steroids)

dependent variables

Modified Rodnan skin score (mRSS)
Pulmonary artery pressure (PAPs) expressed in mmHg
Left ventricular ejection fraction (FE%) evaluated at echocardiography
Diffusion capacity for carbon monoxide (DLCO)
Nailfold-video-capillaroscopy (NVC) pattern (early, active and late)
Macrovascular CDUS parameters (RI and PV)

control variables

Patients fulfilling 2013 ACR/EULAR SSc classification criteria
The results from the SSc group were compared to those of a group of patients affected by primary RP (n = 23) and to HCs (n = 22)
All patients were evaluated under vasodilator treatment except for those receiving iloprost, who were evaluated on a different day with respect to the treatment

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!